Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)
This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. The MTD was 30 mg/m2 clofarabine...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
30 October 2018
|
| In: |
British journal of haematology
Year: 2018, Volume: 183, Issue: 2, Pages: 235-241 |
| ISSN: | 1365-2141 |
| DOI: | 10.1111/bjh.15546 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1111/bjh.15546 Verlag: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15546 
|
| Author Notes: | Jürgen Krauter, Walter Fiedler, Richard F. Schlenk, Peter Paschka, Felicitas Thol, Michael Lübbert, Mohammed Wattad, Mareike Verbeek, Christian Könecke, Barbara Neuhaus, Armin Papkalla, Maxim Kebenko, Melanie Janning, Konstanze Döhner, Verena I. Gaidzik, Heiko Becker, Christine Greil, Peter Reimer, Katharina S. Götze, Hartmut Döhner, Arnold Ganser, Michael Heuser |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1680055607 | ||
| 003 | DE-627 | ||
| 005 | 20230426084706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191028s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.15546 |2 doi | |
| 035 | |a (DE-627)1680055607 | ||
| 035 | |a (DE-599)KXP1680055607 | ||
| 035 | |a (OCoLC)1341249251 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Krauter, Jürgen |e VerfasserIn |0 (DE-588)1198149647 |0 (DE-627)1680055410 |4 aut | |
| 245 | 1 | 0 | |a Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial) |c Jürgen Krauter, Walter Fiedler, Richard F. Schlenk, Peter Paschka, Felicitas Thol, Michael Lübbert, Mohammed Wattad, Mareike Verbeek, Christian Könecke, Barbara Neuhaus, Armin Papkalla, Maxim Kebenko, Melanie Janning, Konstanze Döhner, Verena I. Gaidzik, Heiko Becker, Christine Greil, Peter Reimer, Katharina S. Götze, Hartmut Döhner, Arnold Ganser, Michael Heuser |
| 264 | 1 | |c 30 October 2018 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.10.2019 | ||
| 520 | |a This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. The MTD was 30 mg/m2 clofarabine for patients below and above 60 years. The most frequently reported grade 3-4 non-haematological adverse events were infectious and gastrointestinal toxicities. Complete remission (CR)/CR with incomplete recovery rate was 67%. Allogeneic haematopoietic cell transplantation in first remission was feasible in a high proportion of younger AML patients and probably contributed to the favourable outcome compared to historical controls. | ||
| 650 | 4 | |a acute myeloid leukaemia | |
| 650 | 4 | |a clofarabine | |
| 650 | 4 | |a cytarabine | |
| 650 | 4 | |a idarubicin | |
| 650 | 4 | |a maximum tolerated dose | |
| 700 | 1 | |a Fiedler, Walter |e VerfasserIn |0 (DE-588)1027578748 |0 (DE-627)729427226 |0 (DE-576)373414943 |4 aut | |
| 700 | 1 | |a Schlenk, Richard Friedrich |d 1965- |e VerfasserIn |0 (DE-588)129025380 |0 (DE-627)387778004 |0 (DE-576)297454102 |4 aut | |
| 700 | 1 | |a Paschka, Peter |d 1970- |e VerfasserIn |0 (DE-588)123089840 |0 (DE-627)706156870 |0 (DE-576)293550832 |4 aut | |
| 700 | 1 | |a Thol, Felicitas |d 1977- |e VerfasserIn |0 (DE-588)129633984 |0 (DE-627)475217403 |0 (DE-576)297759329 |4 aut | |
| 700 | 1 | |a Lübbert, Michael |e VerfasserIn |0 (DE-588)1054105367 |0 (DE-627)79104047X |0 (DE-576)409999768 |4 aut | |
| 700 | 1 | |a Wattad, Mohammed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Verbeek, Mareike |d 1976- |e VerfasserIn |0 (DE-588)124945503 |0 (DE-627)368956814 |0 (DE-576)294582185 |4 aut | |
| 700 | 1 | |a Könecke, Christian |d 1976- |e VerfasserIn |0 (DE-588)129502162 |0 (DE-627)707258154 |0 (DE-576)297693514 |4 aut | |
| 700 | 1 | |a Neuhaus, Barbara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Papkalla, Armin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kebenko, Maxim |d 1978- |e VerfasserIn |0 (DE-588)133961702 |0 (DE-627)558836992 |0 (DE-576)300219490 |4 aut | |
| 700 | 1 | |a Janning, Melanie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Döhner, Konstanze |e VerfasserIn |0 (DE-588)1050325176 |0 (DE-627)783856369 |0 (DE-576)404527671 |4 aut | |
| 700 | 1 | |a Gaidzik, Verena Ingeborg |d 1979- |e VerfasserIn |0 (DE-588)130197408 |0 (DE-627)49436369X |0 (DE-576)189417382 |4 aut | |
| 700 | 1 | |a Becker, Heiko |d 1978- |e VerfasserIn |0 (DE-588)1124562494 |0 (DE-627)878761993 |0 (DE-576)482834307 |4 aut | |
| 700 | 1 | |a Greil, Christine |d 1984- |e VerfasserIn |0 (DE-588)143480596 |0 (DE-627)646570862 |0 (DE-576)337291578 |4 aut | |
| 700 | 1 | |a Reimer, Peter |e VerfasserIn |0 (DE-588)1112143831 |0 (DE-627)866093141 |0 (DE-576)476388562 |4 aut | |
| 700 | 1 | |a Götze, Katharina |d 1966- |e VerfasserIn |0 (DE-588)113344309 |0 (DE-627)573832269 |0 (DE-576)28975979X |4 aut | |
| 700 | 1 | |a Döhner, Hartmut |d 1957- |e VerfasserIn |0 (DE-588)110666585 |0 (DE-627)729880842 |0 (DE-576)375358846 |4 aut | |
| 700 | 1 | |a Ganser, Arnold |d 1954- |e VerfasserIn |0 (DE-588)133814300 |0 (DE-627)556252268 |0 (DE-576)300124171 |4 aut | |
| 700 | 1 | |a Heuser, Michael |d 1974- |e VerfasserIn |0 (DE-588)130051918 |0 (DE-627)488792959 |0 (DE-576)297970534 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d Oxford [u.a.] : Wiley-Blackwell, 1955 |g 183(2018), 2, Seite 235-241 |h Online-Ressource |w (DE-627)269758941 |w (DE-600)1475751-5 |w (DE-576)09113997X |x 1365-2141 |7 nnas |a Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial) |
| 773 | 1 | 8 | |g volume:183 |g year:2018 |g number:2 |g pages:235-241 |g extent:7 |a Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial) |
| 856 | 4 | 0 | |u https://doi.org/10.1111/bjh.15546 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15546 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20191028 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 129025380 |a Schlenk, Richard Friedrich |m 129025380:Schlenk, Richard Friedrich |d 910000 |d 910100 |e 910000PS129025380 |e 910100PS129025380 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 999 | |a KXP-PPN1680055607 |e 352924130X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"corporate":[{"display":"British Society for Haematology","role":"isb","roleDisplay":"Herausgebendes Organ"},{"display":"European Hematology Association","role":"isb","roleDisplay":"Herausgebendes Organ"}],"pubHistory":["1.1955 -"],"titleAlt":[{"title":"the official journal of the British Society of Haematology"},{"title":"BJH ; the official journal of the British Society for Haematology"}],"recId":"269758941","note":["Gesehen am 08.05.08"],"disp":"Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)British journal of haematology","id":{"issn":["1365-2141"],"doi":["10.1111/(ISSN)1365-2141"],"eki":["269758941"],"zdb":["1475751-5"]},"title":[{"subtitle":"BJHaem : an official journal of the British Society for Haematology","title_sort":"British journal of haematology","title":"British journal of haematology"}],"part":{"issue":"2","volume":"183","text":"183(2018), 2, Seite 235-241","pages":"235-241","extent":"7","year":"2018"},"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["ed. R. B. Thompson [u.a.]"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedDisp":"1955-","dateIssuedKey":"1955","publisherPlace":"Oxford [u.a.] ; Oxford ; Oxford [u.a.]","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell"}]}],"person":[{"given":"Jürgen","role":"aut","display":"Krauter, Jürgen","family":"Krauter","roleDisplay":"VerfasserIn"},{"given":"Walter","display":"Fiedler, Walter","role":"aut","roleDisplay":"VerfasserIn","family":"Fiedler"},{"roleDisplay":"VerfasserIn","family":"Schlenk","given":"Richard Friedrich","role":"aut","display":"Schlenk, Richard Friedrich"},{"family":"Paschka","roleDisplay":"VerfasserIn","display":"Paschka, Peter","role":"aut","given":"Peter"},{"display":"Thol, Felicitas","role":"aut","given":"Felicitas","roleDisplay":"VerfasserIn","family":"Thol"},{"given":"Michael","display":"Lübbert, Michael","role":"aut","roleDisplay":"VerfasserIn","family":"Lübbert"},{"family":"Wattad","roleDisplay":"VerfasserIn","role":"aut","display":"Wattad, Mohammed","given":"Mohammed"},{"given":"Mareike","role":"aut","display":"Verbeek, Mareike","roleDisplay":"VerfasserIn","family":"Verbeek"},{"given":"Christian","role":"aut","display":"Könecke, Christian","family":"Könecke","roleDisplay":"VerfasserIn"},{"display":"Neuhaus, Barbara","role":"aut","given":"Barbara","family":"Neuhaus","roleDisplay":"VerfasserIn"},{"family":"Papkalla","roleDisplay":"VerfasserIn","role":"aut","display":"Papkalla, Armin","given":"Armin"},{"role":"aut","display":"Kebenko, Maxim","given":"Maxim","roleDisplay":"VerfasserIn","family":"Kebenko"},{"role":"aut","display":"Janning, Melanie","given":"Melanie","family":"Janning","roleDisplay":"VerfasserIn"},{"family":"Döhner","roleDisplay":"VerfasserIn","role":"aut","display":"Döhner, Konstanze","given":"Konstanze"},{"role":"aut","display":"Gaidzik, Verena Ingeborg","given":"Verena Ingeborg","roleDisplay":"VerfasserIn","family":"Gaidzik"},{"display":"Becker, Heiko","role":"aut","given":"Heiko","roleDisplay":"VerfasserIn","family":"Becker"},{"family":"Greil","roleDisplay":"VerfasserIn","display":"Greil, Christine","role":"aut","given":"Christine"},{"roleDisplay":"VerfasserIn","family":"Reimer","given":"Peter","display":"Reimer, Peter","role":"aut"},{"family":"Götze","roleDisplay":"VerfasserIn","role":"aut","display":"Götze, Katharina","given":"Katharina"},{"roleDisplay":"VerfasserIn","family":"Döhner","role":"aut","display":"Döhner, Hartmut","given":"Hartmut"},{"roleDisplay":"VerfasserIn","family":"Ganser","given":"Arnold","display":"Ganser, Arnold","role":"aut"},{"given":"Michael","display":"Heuser, Michael","role":"aut","family":"Heuser","roleDisplay":"VerfasserIn"}],"name":{"displayForm":["Jürgen Krauter, Walter Fiedler, Richard F. Schlenk, Peter Paschka, Felicitas Thol, Michael Lübbert, Mohammed Wattad, Mareike Verbeek, Christian Könecke, Barbara Neuhaus, Armin Papkalla, Maxim Kebenko, Melanie Janning, Konstanze Döhner, Verena I. Gaidzik, Heiko Becker, Christine Greil, Peter Reimer, Katharina S. Götze, Hartmut Döhner, Arnold Ganser, Michael Heuser"]},"physDesc":[{"extent":"7 S."}],"origin":[{"dateIssuedDisp":"30 October 2018","dateIssuedKey":"2018"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"note":["Gesehen am 28.10.2019"],"recId":"1680055607","id":{"doi":["10.1111/bjh.15546"],"eki":["1680055607"]},"title":[{"title":"Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)","title_sort":"Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)"}]} | ||
| SRT | |a KRAUTERJUEPHASEIIIST3020 | ||